An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma

Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SM, Vekeman F, Hlavacek P, Meche A, Kim CH, Cislo P, Hughes DM, Nador G, DiBonaventura M

Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:11-20

Published Date: 5 June 2025